Gene therapy AB-1005: how safe is it years later?

NCT ID NCT07081841

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: AskBio Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB-1005 (gene therapy)
What this could lead to: If successful, this study could show that AB-1005 is safe and has lasting benefits for people with Parkinson's disease or multiple system atrophy.
What could go wrong: This is an observational follow-up, not a new treatment test. It may not prove effectiveness, and results depend on prior study participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY, PARKINSON VARIANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple system atrophy multiple system atrophy, parkinsonian type Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SYSTEM ATROPHY, PARKINSON VARIANT PARKINSON'S DISEASE

Contacts and locations

Locations

Ohio State University

Columbus, Ohio, 43210, United States
University of California San Francisco

San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.